Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Pharma
Astellas shifts investment focus to later-stage programs: exec
As part of a reprioritization, Astellas is shifting its focus more to later-stage opportunities, chief strategy officer Adam Pearson said.
Angus Liu
Feb 12, 2025 1:30pm
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Jan 10, 2025 9:00am
Merck's GLP-1 play; Astellas' AAV deal—Fierce Pharma Asia
Dec 20, 2024 8:51am
Daiichi, BIOSECURE, Amgen—Fierce Pharma Asia
Dec 13, 2024 8:43am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
Jazz's HER2 bispecific snags FDA nod to rival Enhertu
Nov 21, 2024 7:53am
